Kanada - angielski - Health Canada

dr reddy's laboratories ltd - gemcitabine (gemcitabine hydrochloride) - powder - 200mg - gemcitabine (gemcitabine hydrochloride) 200mg - antineoplastic agents

Kanada - angielski - Health Canada

dr reddy's laboratories ltd - gemcitabine (gemcitabine hydrochloride) - powder - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents

Kanada - angielski - Health Canada

dr reddy's laboratories ltd - gemcitabine (gemcitabine hydrochloride) - powder - 2g - gemcitabine (gemcitabine hydrochloride) 2g - antineoplastic agents

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine;  ;   - powder for injection - 200 mg - active: gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine     excipient: mannitol nitrogen sodium acetate as sodium acetate trihydrate sodium hydroxide - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Kanada - angielski - Health Canada

telip, llc, a subsidiary of teligent, inc. - gemcitabine (gemcitabine hydrochloride) - powder for solution - 200mg - gemcitabine (gemcitabine hydrochloride) 200mg - antineoplastic agents

Kanada - angielski - Health Canada

telip, llc, a subsidiary of teligent, inc. - gemcitabine (gemcitabine hydrochloride) - powder for solution - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 227.8 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: dilute hydrochloric acid; water for injections - treatment of patients with locally advanced or metastatic non-small cell lung cancer. ? treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ? treatment of patients with 5fu refractory pancreatic cancer. ? treatment of patients with bladder cancer, alone or in combination with cisplatin. ? treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ? treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - gemcitabine hydrochloride, quantity: 1138 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate trihydrate; sodium hydroxide - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Australia - angielski - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - gemcitabine hydrochloride, quantity: 228 mg - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sodium acetate trihydrate - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Australia - angielski - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gemcitabine hydrochloride, quantity: 228 mg - injection, powder for - excipient ingredients: sodium acetate trihydrate; mannitol; sodium hydroxide - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy